Simplement Spółka z Ograniczoną Odpowiedzialnością Spółka Komandytowa (KRS 0000380435, NIP 1182062319) is a Polish company, headquartered in Janów, Mazowieckie voivodeship. SIMPLEMENT SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since March 15, 2011. SIMPLEMENT SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ's most recently reported net revenue was 0 PLN for 2024.
Negative equity
Negative equity in 2 of 3 available reporting years.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Simplement
Identity
- Name
- Simplement Spółka z Ograniczoną Odpowiedzialnością Spółka Komandytowa
- Legal form
- SPÓŁKA KOMANDYTOWA
- Founded
- March 15, 2011
- Registry status as of
- November 21, 2025
- Latest entry
- July 23, 2025
- Founding act
- UMOWA SPÓŁKI KOMANDYTOWEJ ZAWARTA DNIA 20.01.2011 R. PRZED ASESOREM NOTARIALNYM DAGMARĄ KONOPKĄ, ZASTĘPCĄ NOTARIUSZA WIK…
Articles of association history (2)
- January 20, 2011: UMOWA SPÓŁKI KOMANDYTOWEJ ZAWARTA DNIA 20.01.2011 R. PRZED ASESOREM NOTARIALNYM DAGMARĄ KONOPKĄ, ZASTĘPCĄ NOTARIUSZA WIKTORA WĄGRODZKIEGO, KANCELARIA NOTARIALNA W WARSZAWIE, REP. A NR 1243/2011
- November 25, 2014: 25.11.2014 R., PRZED NOTARIUSZEM MAŁGORZATĄ TOMCZYK-PERŁOWSKĄ PROWADZĄCĄ KANCELARIĘ NOTARIALNĄ W BABICACH NOWYCH (BABICE NOWE, UL. WARSZAWSKA 189,05-082 STARE BABICE) REP. A NR 2174/2014. ZMIENIONO § 2.1, § 2.2, § 3.
Activities
Main activity
72.11.ZResearch and experimental development on biotechnology
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. WŁADYSŁAWA SIKORSKIEGO, 74, 05-082, JANÓW, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWSKI ZACHODNI
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.2624, 20.8593approx.
Risk and payment profile - Simplement
Credibility rating
40 / 100
Poor credibility
Insolvency risk
Very low
Elevated threat
Closure risk
20
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/15 yrs
Board changes
0
0/15 yrs
PKD changes
1
1/15 yrs
Name changes
1
1/15 yrs
Data from 15 years of registry activity.
Credibility history
Payment reliability score from 2019–2024
Current: D (40/100)
Trend: deteriorating (-10.0 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2019–2024
Current: 504.0 K PLN
Safe: 151.2 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Simplement
Founded
March 15, 2011
15 years in operation
Legal form
SPÓŁKA KOMANDYTOWA
Registry: RejP
Headquarters
JANÓW
MAZOWIECKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
N/A
Shareholders
N/A
Board
N/A
Filed years
3 years
2019–2024 · profitable: 1/3
Registry entries
27
latest: July 23, 2025
Risk signals
Revenue
0 PLN
2024
Net profit
0 PLN
2024
Assets
4.2 M PLN
2024
Equity
-754.7 K PLN
2024
EBITDA
0 PLN
2024
Valuation
1.6 M PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Simplement.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
